Dinaciclib, a potent CDK2 inhibitor (as well as CDK1, CDK5, and CDK9 inhibitor) that is currently in clinical trials for several cancers, was used to target the cyclin E/CDK2 pathway. This evidence concerns the gene CCNE1 and cancer.